No connection

Search Results

SBC

NEUTRAL
$4.49 Live
SBC Medical Group Holdings Incorporated · NASDAQ
Target $8.25 (+83.7%)
$2.97 52W Range $5.75

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$460.57M
P/E
8.98
ROE
22.3%
Profit margin
29.4%
Debt/Equity
0.2
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
75%
SBC presents a paradoxical profile: it is fundamentally undervalued with a P/E of 8.98 and a price below its Graham Number ($5.22), yet it exhibits weak financial health with a Piotroski F-Score of 3/9. While profitability margins are impressive (Gross Margin 73.32%), the company is facing negative revenue growth (-10.90%) and significant insider selling by the CEO. The disconnect between the 'Buy' analyst consensus and the bearish technical/insider trends suggests a high-risk value play with deteriorating fundamentals.

Key Strengths

Very low P/E ratio (8.98) relative to sector average (79.88)
Strong profitability margins (Gross: 73.32%, Operating: 32.47%)
Excellent liquidity with a Current Ratio of 3.78
Low leverage with a Debt/Equity ratio of 0.20
Trading below both Graham Number ($5.22) and Intrinsic Value ($14.75)

Key Risks

Weak Piotroski F-Score (3/9) indicating deteriorating financial health
Negative YoY and Q/Q revenue growth (-10.90%)
Massive insider selling by the CEO ($16.45M)
Highly inconsistent earnings track record with extreme surprises (e.g., -98.7% in 2024)
Severe long-term price depreciation (5Y change of -54.9%)
AI Fair Value Estimate
Based on comprehensive analysis
$6.5
+44.8% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
37
Weak
Value
85
Future
40
Past
30
Health
30
Dividend
0
AI Verdict
Speculative Value
Key drivers: Deep valuation discount, Negative revenue growth, Poor Piotroski health score, Aggressive insider selling
Confidence
80%
Value
85/100

Stock is significantly undervalued based on P/E and Graham Number compared to Industrials sector peers.

Positives
  • P/E of 8.98 is extremely low
  • Price is below Graham Number of $5.22
Watchpoints
  • Low market cap increases volatility
Future
40/100

Growth metrics are contradictory; earnings are rising while the top line is contracting.

Positives
  • Strong YoY earnings growth (117.5%)
Watchpoints
  • Revenue is shrinking (-10.9%)
  • Earnings growth appears decoupled from revenue
Past
30/100

Long-term historical performance is poor, suggesting a chronic decline.

Positives
  • Recent 1-month price surge (+28.3%)
Watchpoints
  • 3Y and 5Y returns are deeply negative (-57% and -54.9%)
Health
30/100

Despite a clean balance sheet, the F-Score indicates negative trends in operational efficiency and financial strength.

Positives
  • Low Debt/Equity (0.20)
  • High Current Ratio (3.78)
Watchpoints
  • Piotroski F-Score of 3/9 is in the 'Weak' category
Dividend
0/100

Company does not return capital to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$4.49
Analyst Target
$8.25
Upside/Downside
+83.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SBC and closest competitors.

Updated 2026-04-17
SBC
SBC Medical Group Holdings Incorporated
Primary
5Y
-54.9%
3Y
-57.0%
1Y
+11.7%
6M
+7.0%
1M
+28.3%
1W
+8.2%
CYR
Cryoport, Inc.
Peer
5Y
-82.9%
3Y
-56.6%
1Y
+67.8%
6M
-6.0%
1M
+13.8%
1W
+11.2%
ACT
Acacia Research Corporation
Peer
5Y
-23.6%
3Y
+8.4%
1Y
+35.2%
6M
+48.3%
1M
+20.2%
1W
+19.6%
AIR
Air T, Inc.
Peer
5Y
+27.4%
3Y
+17.1%
1Y
+23.6%
6M
+8.2%
1M
-1.4%
1W
+0.0%
ISS
Innovative Aerosystems, Inc.
Peer
5Y
+288.5%
3Y
+235.2%
1Y
+335.5%
6M
+118.7%
1M
-16.0%
1W
+11.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
8.98
Forward P/E
8.98
PEG Ratio
N/A
P/B Ratio
1.86
P/S Ratio
2.65
EV/Revenue
2.09
EV/EBITDA
5.17
Market Cap
$460.57M

Profitability

Profit margins and return metrics

Profit Margin 29.37%
Operating Margin 32.47%
Gross Margin 73.32%
ROE 22.27%
ROA 13.05%

Growth

Revenue and earnings growth rates

Revenue Growth -10.9%
Earnings Growth +117.5%
Q/Q Revenue Growth -10.93%
Q/Q Earnings Growth +117.2%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.2
Low debt
Current Ratio
3.78
Strong
Quick Ratio
3.56
Excellent
Cash/Share
$1.6

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
73.1%
Op. Margin
32.5%
Net Margin
35.9%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.2B
Debt/Equity
0.47x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
98%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-27
$0.14
+16.7% surprise
2025-11-14
$0.12
+5.9% surprise
2025-08-13
$0.02
-85.2% surprise

Industrials Sector Comparison

Comparing SBC against 317 companies in the Industrials sector (22 bullish, 106 neutral, 189 bearish)
P/E Ratio
8.98
This Stock
vs
78.37
Sector Avg
-88.5% (Discount)
Return on Equity (ROE)
22.27%
This Stock
vs
-22.02%
Sector Avg
-201.1% (Below Avg)
Profit Margin
29.37%
This Stock
vs
8.66%
Sector Avg
+239.0% (Superior)
Debt to Equity
0.2
This Stock
vs
2.99
Sector Avg
-93.4% (Less Debt)
Revenue Growth
-10.9%
This Stock
vs
99.96%
Sector Avg
-110.9% (Slower)
Current Ratio
3.78
This Stock
vs
3.33
Sector Avg
+13.5% (Better)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

AIKAWA YOSHIYUKI
Chief Executive Officer
Sell
2026-03-06
4,422,900 shares · $16,453,188
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
4 analysts
BTIG
2026-03-06
init
Buy

Past News Coverage

Recent headlines mentioning SBC from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile